⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.

Official Title: A PHASE 1B/2, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF ELRANATAMAB (PF-06863135) IN CHINESE PARTICIPANTS WITH MULTIPLE MYELOMA WHO ARE REFRACTORY TO AT LEAST ONE PROTEASOME INHIBITOR, ONE IMMUNOMODULATORY DRUG AND ONE ANTI-CD38 ANTIBODY (TRIPLE-CLASS REFRACTORY MM)

Study ID: NCT05228470

Interventions

Elranatamab

Study Description

Brief Summary: The purpose of this study is to understand the study medicine (called Elranatamab, or PF-06863135) as potential treatment for refractory multiple myeloma. Multiple myeloma is a form of cancer in the bone that forces healthy blood cells to go out. Sometimes, multiple myeloma does not respond to current therapy or quickly progresses, and this is called refractory multiple myeloma. Elranatamab is a study medicine that target multiple myeloma and activates the human body to fight against this disease. We are seeking Chinese participants to take part in this study. The study will be 2 parts, called part 1b and part 2. In part 1b, participants will receive Elranatamab at 2 steps priming and full dose as a sc (subcutaneous injection) therapy. We will monitor participants' safety and reactions to the study medicine. This will help us understand the dosage of Elranatamab to be used safely. In part 2 of the study, participants will receive Elranatamab and their multiple myeloma growth will be monitored. This will help us understand if Elranatamab, when used alone, may be a therapy for refractory multiple myeloma. Participants in this part of the study are expected to take part for about 2 years.

Detailed Description:

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Fujian Medical University Union Hospital, Fuzhou, Fujian, China

Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China

Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Shenzhen Second People's Hosptial, Shenzhen, Guangdong, China

Harbin First Hospital, Harbin, Heilongjiang, China

Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China

Henan Cancer Hospital, Zhengzhou, Henan, China

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

Nanjing Drum Tower Hospital,The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China

The First Hospital of Jilin University, Changchun, Jilin, China

Shandong Provincial Hospital, Jinan, Shandong, China

The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China

The First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China

Beijing Boren Hospital, Beijing, , China

Beijing Gaobo Boren Hospital, Beijing, , China

Peking University Third Hospital, Beijing, , China

Peking Union Medical College Hospital, Beijing, , China

Hematology Hospital, Chinese Academy of Medical Sciences, Tianjin, , China

Tianjin Medical University General Hospital, Tianjin, , China

Contact Details

Name: Pfizer CT.gov Call Center

Affiliation: Pfizer

Role: STUDY_DIRECTOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: